We are pleased to announce that our basic research on the radiosensitizer KORTUC has been published in Radiotherapy & Oncology “ Green Journal”, a leading journal in radiation oncology. This study, conducted in collaboration with UZ Brussel (Brussels, Belgium) led by Dr. Mark De Ridder, sheds light on KORTUC’s novel mechanism of action and its potential to overcome tumor hypoxia—a major challenge in radiotherapy.
The study, titled “Revisiting Hydrogen Peroxide as a Radiosensitizer for Solid Tumor Cells,” demonstrates that KORTUC suppresses oxygen consumption in hypoxic tumor cells via mitochondrial pathways, restores oxygen levels, and significantly enhances the effects of radiotherapy.
Comments by Kazuyuki Matsuda (KORTUC CEO)
Currently, we are conducting a pivotal Phase 2 clinical trial in breast cancer and planning to start clinical trials in rectal and cervical cancers. We aim to launch KORTUC in the EU and US markets, with a vision to expand globally. This research is a significant step in advancing KORTUC’s role in redefining the role of radiotherapy as standard of cancer treatment.
Read the full study here: The Green Journal Abstract